Ovulation Inhibition under treatment with Relugolix in combination with estradiol and norethindrone acetate

News of Oktober 12th, 2020

We are pleased to announce that together with the colleagues from Dinox and SocraMetrics as well as the experts from Myovant we have recently published our newest study in the field of ovulation inhibition: the once-daily, oral gonadotropin-releasing hormone receptor antagonist, Relugolix, in combination with estradiol and norethindrone acetate in healthy premenopausal women has been characterised in regards to influence on suppression of ovulation as well as interference with pituitary hormones and further gynecological endpoints. Data have been presented at the virtual 36th Annual Meeting oft he European Society of Human Reproduction and Embryology in July 2020

All fine on single